Ann: Trading Halt, page-4

Agree.

With the prior announcement falling prior to the halt, has to looking positive.

Appointment of Dr Tony Keating as Executive Director & Resignation of Dr Tom Young Highlights: • Appointment of Dr Tony Keating as part time Executive Director, effective 29 July 2024
•Dr Keating brings extensive experience as a healthcare executive, having co-founded ResApp Health and led it through commercialisation, culminating in a $180m acquisition by global biopharmaceutical company Pfizer in 2022
• Along with his track record in commercialising AI-based digital health technology, Dr Keating brings advanced knowledge of the US regulatory landscape and strong networks in the global healthcare industry
• Appointment strengthens the composition of the Board ahead of pending results of TRI’s comprehensive Phase 2 SAMDE study for TrivarX’s proprietary MEB-001 algorithm which assists with the effective screening of a current Major Depressive Episode (cMDE)
• Resignation of Dr Thomas Young as Non-Executive Director, effective 29 July 2024